Medications for Nonradiographic Axial Spondyloarthritis
5 results
Bimzelx (bimekizumab)
(bimekizumab)UCB, Inc.
Usage: BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who are candidates for systemic therapy or phototherapy.
Cimzia (certolizumab pegol)
(certolizumab pegol)UCB, Inc.
Usage: CIMZIA is indicated for treating adults and certain pediatric patients with moderately to severely active Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and moderate-to-severe plaque psoriasis. It is also used for polyarticular juvenile idiopathic arthritis and non-radiographic axial spondyloarthritis with objective signs of inflammation.
Cosentyx (secukinumab)
(secukinumab)Novartis Pharmaceuticals Corporation
Usage: COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in patients 2 years and older, ankylosing spondylitis in adults, non-radiographic axial spondyloarthritis in adults, active enthesitis-related arthritis in patients 4 years and older, and moderate to severe hidradenitis suppurativa in adults.
Rinvoq (upadacitinib)
(Upadacitinib)AbbVie Inc.
Usage: RINVOQ is indicated for adults and pediatric patients (2 years and older) with conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis, after inadequate response to TNF blockers.
Taltz (ixekizumab)
(ixekizumab)Eli Lilly and Company
Usage: TALTZ is indicated for treating moderate-to-severe plaque psoriasis in patients aged 6 and older, active psoriatic arthritis in adults, active ankylosing spondylitis in adults, and active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation.